Form 4: Labcorp EVP Caveney Boosts Equity Holdings

Labcorp's EVP, Brian J. Caveney, increased his equity stake by acquiring 6,100 non-qualified stock options and 2,020 restricted stock units on February 10, 2026.

Summary

• Brian J. Caveney, EVP, President of ED, CMO & CSO of Labcorp Holdings Inc. (LH), reported an acquisition of securities.
• On February 10, 2026, Caveney acquired 6,100 non-qualified stock options with an exercise price of $284.5 per share.
• These options will vest in three equal annual installments, beginning on February 10, 2027, and expire on February 9, 2036.
• Additionally, Caveney acquired 2,020 Restricted Stock Units (RSUs) on February 10, 2026.
• Each RSU represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.
• The RSUs will vest in three equal annual installments, beginning on February 10, 2027.
• Following these transactions, Caveney beneficially owns 6,100 non-qualified stock options and an aggregate of 4,910 Restricted Stock Units.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive compensation practices that align management incentives with long-term shareholder value, without indicating any immediate operational or financial shifts.

Positives

• Increased equity ownership by a key executive, Brian J. Caveney, aligns his interests with those of shareholders.
• The grant of non-qualified stock options and Restricted Stock Units is a standard component of executive compensation, incentivizing long-term performance.

Future Outlook

The vesting schedules for the acquired stock options and Restricted Stock Units, extending to February 2027 and beyond, indicate a long-term incentive structure for executive Brian J. Caveney, aligning his future performance with shareholder value creation.

Industry Context

StockSavvy.ai notes that the grant of equity awards, such as stock options and Restricted Stock Units, is a common practice in executive compensation across the healthcare and diagnostics industry. This strategy aims to align the long-term interests of executives with those of shareholders by tying a significant portion of their compensation to the company's stock performance and sustained growth.

Comparison to Industry Standards

• Equity-based compensation, including stock options and RSUs, is a standard practice for executive remuneration in large publicly traded companies, particularly within the healthcare and life sciences sectors, similar to peers like Quest Diagnostics or Thermo Fisher Scientific.
• The vesting schedule over multiple years is typical for long-term incentive plans, designed to retain key talent and encourage sustained performance, comparable to structures seen at companies like Danaher Corporation or Abbott Laboratories.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of executive interests with long-term company performance and shareholder value.
• Employees: No direct impact on general employees, but reflects the company's executive compensation strategy.

Next Steps

• Vesting of 6,100 non-qualified stock options in three equal annual installments beginning February 10, 2027.
• Vesting of 2,020 Restricted Stock Units in three equal annual installments beginning February 10, 2027.

Key Dates

Recommendation

This Form 4 filing is a routine disclosure of executive equity compensation and does not present new material information that would fundamentally alter the investment thesis for Labcorp Holdings Inc. It confirms standard practices for incentivizing management but does not provide insights into operational performance or strategic shifts that would warrant a change in recommendation.

Keywords

Labcorp, LH, Insider Transaction, Executive Compensation, Stock Options, Restricted Stock Units, Brian J. Caveney, Equity Grant